NCT06208306
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
Campos del registro
- Estado general
- COMPLETED
- Condiciones
- Chronic Obstructive Pulmonary Disease
- Tipo de estudio
- INTERVENTIONAL
- Fase
- PHASE3
- Objetivo principal
- TREATMENT
- Tipo de intervención
- DRUG
- Intervenciones
- Itepekimab (SAR440340), Placebo
- Patrocinador principal
- Sanofi (INDUSTRY)
En caché: 2026-10-25 15:54:50
Resumen breve
This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment response, and provide additional PK and immunogenicity assessments.
The primary purpose of this study is to evaluate safety and tolerability of both itepekimab SC Q2W or itepekimab SC Q4W in participants with COPD having completed the treatment period of the clinical studies EFC16750 or EFC16819. A secondary purpose of this study is to provide efficacy outcomes beyond the treatment period of the parent trials EFC16750 and EFC16819.
Study details include:
* The study duration will be up to 72 weeks
* The treatment duration will be up to 52 weeks
* A follow-up period of 20 weeks will be conducted
* The number of on-site visits will be 7 and the number of phone contacts will be 5
The primary purpose of this study is to evaluate safety and tolerability of both itepekimab SC Q2W or itepekimab SC Q4W in participants with COPD having completed the treatment period of the clinical studies EFC16750 or EFC16819. A secondary purpose of this study is to provide efficacy outcomes beyond the treatment period of the parent trials EFC16750 and EFC16819.
Study details include:
* The study duration will be up to 72 weeks
* The treatment duration will be up to 52 weeks
* A follow-up period of 20 weeks will be conducted
* The number of on-site visits will be 7 and the number of phone contacts will be 5
Contacto
¿Necesita un informe o redacción médica basada en este ensayo?
Iniciar sesión con Kakao para continuar